TimesSquare Capital Management recently disclosed its investment strategy for the fourth quarter of 2025, drawing attention to Axogen, Inc., a company at the forefront of peripheral nerve regeneration. This move underscores a broader interest in healthcare innovations and the pursuit of novel therapeutic solutions.

TimesSquare Capital Backs Axogen in Q4 2025, Citing Innovative Nerve Repair Technology

In the final quarter of 2025, TimesSquare Capital Management, a prominent equity investment firm, released its U.S. Small Cap Growth Strategy investor letter. The letter detailed the strategy's impressive performance, achieving a 3.70% gross return (3.45% net) during the quarter, significantly outpacing the Russell 2000 Growth Index's 1.22% return. For the entirety of 2025, the strategy yielded a 6.91% gross return (5.85% net), albeit trailing the index's 13.01%. This period saw a positive global equity market, with Europe leading the charge and large-cap stocks generally outperforming their small-cap counterparts. Despite an extended trade truce between the U.S. and China, geopolitical uncertainties persisted, influencing market dynamics. Amidst these conditions, Axogen, Inc. (NASDAQ:AXGN), a biotechnology and medical services company, emerged as a key investment for TimesSquare Capital.

Axogen, Inc., trading under the NASDAQ symbol AXGN, specializes in developing advanced technologies for the regeneration and repair of peripheral nerves, addressing injuries stemming from trauma, chronic conditions, or surgical procedures. On April 1, 2026, Axogen's shares closed at $33.58, demonstrating a robust one-month return of 15.16% and an astounding 97.07% gain over the preceding 52 weeks. The company boasts a market capitalization of $1.74 billion. TimesSquare Capital specifically lauded Axogen for its flagship product, the Avance Nerve Graft, a pioneering decellularized human nerve allograft. This innovative product maintains the native nerve's microarchitecture while effectively mitigating the risk of immune rejection, making it the sole FDA-approved implantable biological nerve allograft currently available on the market.

The investment community has also taken notice, with 26 hedge fund portfolios holding Axogen, Inc. at the close of Q4 2025, an increase from 20 in the prior quarter. This growing interest highlights the company's potential. In Q4 2025, Axogen reported revenues of $59.9 million, marking a 21.3% year-over-year increase. While acknowledging Axogen's promising trajectory, TimesSquare Capital's letter also hinted that certain AI stocks might offer superior upside potential with reduced downside risk, suggesting a diverse approach to their investment philosophy.

Axogen's journey in nerve regeneration offers a compelling narrative of scientific advancement meeting market opportunity. The firm's dedication to solving complex medical challenges, particularly in an area with significant unmet needs, positions it as a vital player in the biotechnology sector. This case underscores the importance of strategic investments in innovative companies that not only promise financial returns but also contribute meaningfully to human health and well-being. It also highlights the ever-evolving nature of investment strategies, as firms continually weigh the potential of established innovators against emerging trends in high-growth sectors like artificial intelligence.